This includes exploring investigational PI3K and AKT inhibitors to target hyperactive signaling in PTEN-deficient cancers, combining these inhibitors with standard therapies or immunotherapy to enhance treatment effectiveness, and using PTEN profiling as a predictive biomarker to guide personalized treatment approaches. This evidence concerns the gene AKT1 and cancer.